Conflict of interest statement: In relation to this presentation, we declare the 
following, real or perceived conflicts of interest: M. van den Bent has received 
grants from Abbvie, and honoraria from Cellgene, BMS, Boehringer, AGIOS and 
VaXIMM. A. Azaro has received consulting fees from Orion Pharmaceuticals and 
Amcure GmbH. F. De Vos has received financial support for conducting clinical 
trials from Novartis, BMS, AbbVie and Bioclin. J.M. Sepulveda has received 
consulting fees from Celgene, Pfizer and Abbvie; he has received research grants 
from Pfizer and Catalysis. W.K.A. Yung holds stocks in DNATrix; he has received 
honoraria from DNATrix and Boehringer Ingelheim; he holds patents, royalties 
and/or intellectual property in, and has participated in a consulting or 
advisory role for DNATrix; he has received travel and/or accommodation expenses 
from Boehringer Ingelheim. P. Wen has received grants/research support from 
Lilly USA, Agios, AstraZeneca, Beigene, Eli Lily, Immunocellular Therapeutics, 
Kazai, Kadmon, Karyopharm, Merck, Novartis, Oncoceutics, Vascular Biogenics and 
Vaccines; he has received speaker’s bureau fees from Merck; he has received 
consultant/advisory board fees from Genentech/Roche, Taiho Oncology, Novartis, 
Agios Pharmaceuticals Inc, Merck, Puma, Abbvie, AstraZeneca, Eli Lilly, GW 
Pharmaceuticals, Immunomic Therapeutics, Kadmon, Vascular Biogenics, Ziopharm, 
Monteris and Tocagen. A. Lassman reports grants and non-financial support from 
Novartis, during the conduct of the study; personal fees and non-financial 
support from Orbus, grants, personal fees and non-financial support from 
Karyopharm, personal fees and non-financial support from NW Biotherapeutics, 
grants and non-financial support from Oncoceutics, personal fees and 
non-financial support from Agios, personal fees and non-financial support from 
Celgene, personal fees and non-financial support from Novocure, non-financial 
support from Tocagen, non-financial support from BMS, grants, personal fees and 
non-financial support from Kadmon, grants and non-financial support from 
Genentech/Roche, grants and non-financial support from Amgen, grants and 
non-financial support from Millenium, non-financial support from Celldex, grants 
and non-financial support from Pfizer, non-financial support from Keryx/Aeterna 
Zentaris, grants and non-financial support from VBI Vaccines, grants and 
non-financial support from Beigene, personal fees from Bioclinica as an expert 
blinded independent reviewer of clinical and imaging data for a BMS-sponsored 
trial, personal fees from prIME Oncology, personal fees and non-financial 
support from Sapience, personal fees from WebMD, personal fees and non-financial 
support from Physicians' Education Resource, personal fees from Cortice, grants, 
personal fees and non-financial support from AbbVie, personal fees and 
non-financial support from Forma, personal fees and non-financial support from 
Bayer, grants and non-financial support from Global Coalition for Adaptive 
Research, personal fees and non-financial support from American Society of 
Clinical Oncology, grants and non-financial support from QED, grants, personal 
fees and non-financial support from NCI, non-financial support from New York 
University, grants and non-financial support from NRG Oncology/RTOG-Foundations, 
grants from UCLA, grants from Northwestern University, grants from James S. 
McDonnell Foundation, non-financial support from Yale University, non-financial 
support from Radiological Society of North America, non-financial support from 
FDA, personal fees from Italian Foundation for Cancer Research, personal fees 
and non-financial support from Abbott Molecular, and personal fees from 
Elsevier, outside the submitted work M. Joerger has received grants from BMS and 
AstraZeneca. G. Tabatabai has served on Advisory Boards for AbbVie and BMS, has 
received research/travel grants from Medac, Novocure and Roche Diagnostics, and 
has received speaker`s fees from Meda and Novocure. J. Rodon reports 
non-financial support and reasonable reimbursement for travel from European 
Journal of Cancer, Vall d'Hebron Institut of Oncology, Chinese University of 
Hong Kong, SOLTI, Elsevier, GlaxoSmithKline; receiving consulting and travel 
fees from Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, 
Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceutical/Klus Pharma, Spectrum 
Pharmaceuticals Inc, Pfizer, Roche Pharmaceuticals, Ellipses Pharma (including 
serving on the scientific advisory board from 2015-present), receiving research 
funding from Bayer and Novartis, and serving as investigator in clinical trials 
with Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAtla, Pfizer, GenMab, 
CytomX, Kelun-Biotech, Takeda-Millenium, GlaxoSmithKline, IPSEN and travel fees 
from ESMO, US Department of Defense, Louissiana State University, Hunstman 
Cancer Institute, Cancer Core Europe, Karolinska Cancer Institute and King 
Abdullah International Medical Research Center (KAIMRC). R. Tiedt, T. Kirsilae 
and S. Vicente are employees of Novartis Pharma AG. S. Zhao is an employee of 
Novartis Institutes for Biomedical Research (China). A. Balbin is an employee of 
Novartis Institutes for Biomedical Research (US). H. Zhang is an employee of 
Novartis and holds shares with Novartis. W. Wick receives study support to the 
institution from Apogenix, Pfizer and Roche.